Prospective Clinical Applications of CRF Peptide Antagonists

Author(s): Jean E. Rivier*

Journal Name: Current Molecular Pharmacology

Volume 10 , Issue 4 , 2017


Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Abstract:

It is noteworthy that thirty three years of efforts in corticotropin releasing factor (CRF) research by academia and the pharmaceutical industry resulted in several thousand papers and patents, yet little progress has been made to identify and market diagnostic or therapeutic CRF peptides and small molecule ligands. We document the potential relevance of CRF peptide antagonists to reinvigorate stress/anxiety affected “anatomy systems” in order to boost their efficacy.

Keywords: CRF pharmacology, CRF antagonists, CRF receptors, CRF1, CRF2, astressin, astressin B, astressin2-B, [DPhe12]CRF, human/rat CRF (h/rCRF), ovine CRF (oCRF), α-hel CRF(9–41), immune system, cancer, irritable bowel syndrome (IBS), bacteria resistant antibiotics.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 10
ISSUE: 4
Year: 2017
Published on: 03 October, 2017
Page: [264 - 269]
Pages: 6
DOI: 10.2174/1874467210666170110112914
Price: $65

Article Metrics

PDF: 34
HTML: 4
EPUB: 1